Combining CAR-T cells and allo-transplant: what a fascinating approach! ⁦NEJM⁩ ⁦IACH⁩ ⁦The EBMT⁩ ⁦Florent Malard⁩ ⁦Rémy Duléry⁩

Another week, another podcast!🎉

This week, hear from Mohamad Mohty, Ernst Holler & Florent Malard, who discuss novel agents in acute/chronic #GvHD , the role of the gut microbiome & how this can be manipulated:

👉 ow.ly/Yjip50RoVv7

@theEBMT #BMTsm #HemOnc

Combining CAR-T cells and allo-transplant: what a fascinating approach! ⁦NEJM⁩ ⁦IACH⁩ ⁦The EBMT⁩ ⁦Florent Malard⁩ ⁦Rémy Duléry⁩

10) Finally the route to accelerated approval requires expertise and experience in a given disease and the risks and benefits of interventions and the endpoints.

It requires collaboration of regulators, Pharma, investigators, patients, and patient organizations.

9) Disease matters.

Extrapolating failures from various hard to treat cancers where response often doesn’t equate clinical benefit (either because the measurement is flawed or the benefit achievable with our current understanding is small) to all cancers is a fallacy.

8) Accelerated approval thus balances the benefit of having access to effective drugs early versus the risks of incorrectly approving a useless or harmful drug.

Done right, in a disease like myeloma with reliable biomarkers, accelerated approval saves a large number of lives.

7) Important: The purpose of accelerated approval is to help patients. That is our one and only goal.

We do not want a net loss of lives because we are focused on being text book perfect. It’s a risk benefit judgment call.

6) Important: If a drug approved is priced exorbitantly it doesn’t mean the whole accelerated approval pathway is at fault.

It means we have to separately reform the way drug prices in the US are set to be proportional to the added value they provide. It is a concern.

5) Important: If a confirmatory trial is not done in a timely manner that doesn’t mean the accelerated approval pathway is wrong.

It means either regulators for a good reason have allowed a delay (or lack) of such a trial; or lacking such a reason it means they need to enforce

4) Important: If a confirmatory trial is negative that doesn’t mean the whole accelerated approval pathway is at fault.

A small proportion of confirmatory trials will be negative — that means we have followed the principles of accelerated approval (see second tweet in thread).

3) Accelerated approval is predicated on confirmatory trials being done in a timely manner.

Failure to do so should usually result in withdrawal of the accelerated approval. The FDA is currently being quite strict on this aspect.

2) The mechanism is not meant to be 100% fool proof because with such a high bar sensitivity will be low and many truly active drugs will be rejected incorrectly or greatly delayed.

But it needs to be as rigorous as is reasonable so we don’t approve too many ineffective drugs.

On Accelerated Approval

1) In life threatening diseases like cancer the rapid approval of promising new drugs based on phase II data and/or surrogate endpoints is reasonable because waiting for full approval may result in more lives lost due to delay in approval of active drugs.

Table Ronde Francophone autour des données les plus marquantes du 50ème congrès de l’ #ebmt24
Inscription: us06web.zoom.us/webinar/regist…
⁦IACH⁩ ⁦SFGM-TC⁩ ⁦Association Laurette Fugain⁩ ⁦Association des Internes en Hématologie⁩ ⁦Hématologie⁩ ⁦Hématologie Hopital Cochin⁩ ⁦SMH Hematology⁩

Table Ronde Francophone autour des données les plus marquantes du 50ème congrès de l’ #ebmt24
Inscription: us06web.zoom.us/webinar/regist…
⁦IACH⁩ ⁦SFGM-TC⁩ ⁦Association Laurette Fugain⁩ ⁦Association des Internes en Hématologie⁩ ⁦Hématologie⁩ ⁦Hématologie Hopital Cochin⁩ ⁦SMH Hematology⁩

The 10th World COMy Congress is taking place in one month!

We're so excited to attend - hear from Mohamad Mohty, who is inviting you to celebrate this milestone in the beautiful city of Paris 🇫🇷

🗓️ May 23-26

👉 ow.ly/Ggvy50RmT8O

COMy #MMsm #COMy24

We are LIVE NOW!
🔽🔽🔽
bit.ly/3Um2uKv

DLI After Allogeneic Stem Cell Transplantation:
Where Do We Stand?

FREE REGISTRATION

Mohamad Mohty panagiotis tsirigotis

«Prevention and management of acute toxicities from conditioning regimens during HSCT» published in Clin Hematol Int, the official peer-reviewed academic open access journal of ⁦IACH⁩ - No submission fees, page charges or other hidden costs chi.scholasticahq.com/article/94952-…

📢Join us TODAY

DLI After Allogeneic Stem Cell Transplantation: Where Do We Stand?

Register for FREE⏩ bit.ly/3Um2uKv

Mohamad Mohty panagiotis tsirigotis

«Prevention and management of acute toxicities from conditioning regimens during HSCT» published in Clin Hematol Int, the official peer-reviewed academic open access journal of ⁦IACH⁩ - No submission fees, page charges or other hidden costs chi.scholasticahq.com/article/94952-…